{"id":608642,"date":"2024-06-07T18:55:37","date_gmt":"2024-06-07T22:55:37","guid":{"rendered":"https:\/\/platohealth.ai\/astrazeneca-gsk-identify-early-treatment-opportunities-with-big-impact-for-cancer-patients\/"},"modified":"2024-06-08T04:53:42","modified_gmt":"2024-06-08T08:53:42","slug":"astrazeneca-gsk-identify-early-treatment-opportunities-with-big-impact-for-cancer-patients","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/astrazeneca-gsk-identify-early-treatment-opportunities-with-big-impact-for-cancer-patients\/","title":{"rendered":"AstraZeneca, GSK identify early treatment opportunities with big impact for cancer patients","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Product Development<\/p>\n

\n
\n
\n

BioCentury\u2019s ASCO wrap includes analysis of Tagrisso, Imfinzi and Jemperli readouts<\/h2>\n

\n By Lauren Martz, Executive Director, Biopharma Intelligence<\/span>\n<\/p>\n

June 7, 2024 10:55 PM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

The 2024 ASCO conference has proven just how transformational targeted and immunotherapies can be when they\u2019re applied early in disease. As cancer treatments become more effective and less toxic, moving them up in the treatment paradigm \u2014 into entirely new settings for systemic therapies \u2014 is putting cures within reach for more patients. <\/p>\n

Several of the biggest readouts presented at this year\u2019s American Society of Clinical Oncology (ASCO) conference highlight new opportunities for systemic therapies that didn\u2019t exist before. These are places where patient outcomes can be dramatically improved by preventing disease recurrence or avoiding life-altering surgeries, and where untapped commercial opportunity exists. …<\/p>\n